Daprodustat
Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease.[1] It is a hypoxia-inducible factor prolyl hydroxylase inhibitor.[1] It is taken by mouth.[1]
![]() | |
Clinical data | |
---|---|
Trade names | Duvroq, Jesduvroq |
Other names | GSK1278863 |
License data |
|
Routes of administration | By mouth |
Drug class | Hypoxia-inducible factor prolyl hydroxylase inhibitor |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.219.426 |
Chemical and physical data | |
Formula | C19H27N3O6 |
Molar mass | 393.440 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects include high blood pressure, thrombotic vascular events, abdominal pain, dizziness and allergic reactions.[2]
Daprodustat was approved for medical use in Japan in June 2020,[3][4] and in the United States in February 2023.[1][2][5], making it the first oral treatment for anemia caused by chronic kidney disease for adults in the US.[2]
History
Daprodustat increases erythropoietin levels.[2] The effectiveness of daprodustat was established in a randomized study of 2,964 adult participants receiving dialysis.[2] In this study, participants received either oral daprodustat or injected recombinant human erythropoietin (a standard of care treatment for people with anemia due to chronic kidney disease).[2] Daprodustat raised and maintained the hemoglobin (the protein in red blood cells that carries oxygen and is a common measure of anemia) within the target range of 10-11 grams/deciliter, similar to that of the recombinant human erythropoietin.[2] The US Food and Drug Administration (FDA) granted the approval of Jesduvroq to GlaxoSmithKline LLC.[2]
Society and culture
Due to its potential applications in athletic doping, it has also been incorporated into screens for performance-enhancing drugs.[6]
Research
Daprodustat is in phase III clinical trials for the treatment of anemia caused by chronic kidney disease.[7][8][9]
References
- "Jesduvroq- daprodustat tablet, film coated". DailyMed. 1 February 2023. Archived from the original on 11 February 2023. Retrieved 11 February 2023.
- "FDA Approves First Oral Treatment for Anemia Caused by Chronic Kidney Disease for Adults on Dialysis". U.S. Food and Drug Administration (FDA) (Press release). 1 February 2023. Archived from the original on 4 February 2023. Retrieved 3 February 2023.
This article incorporates text from this source, which is in the public domain.
- Dhillon S (September 2020). "Daprodustat: First Approval". Drugs. 80 (14): 1491–1497. doi:10.1007/s40265-020-01384-y. PMC 7471535. PMID 32880805.
- "GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease" (Press release). GSK. 29 June 2020. Archived from the original on 4 February 2023. Retrieved 29 March 2021.
- Harris, Emily (15 February 2023). "FDA Approves First Oral Treatment for Kidney Disease–Induced Anemia". Medical News in Brief. JAMA. 329 (9): 704. doi:10.1001/jama.2023.1556. PMID 36790833.
- Thevis M, Milosovich S, Licea-Perez H, Knecht D, Cavalier T, Schänzer W (August 2016). "Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls". Drug Testing and Analysis. 8 (8): 858–63. doi:10.1002/dta.1870. PMID 26361079.
- Schmid H, Jelkmann W (August 2016). "Investigational therapies for renal disease-induced anemia". Expert Opinion on Investigational Drugs. 25 (8): 901–16. doi:10.1080/13543784.2016.1182981. PMID 27122198. S2CID 32493057.
- Ariazi JL, Duffy KJ, Adams DF, Fitch DM, Luo L, Pappalardi M, et al. (December 2017). "Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia". The Journal of Pharmacology and Experimental Therapeutics. 363 (3): 336–347. doi:10.1124/jpet.117.242503. PMID 28928122.
- Singh, Ajay K.; Carroll, Kevin; McMurray, John J.V.; Solomon, Scott; Jha, Vivekanand; Johansen, Kirsten L.; Lopes, Renato D.; Macdougall, Iain C.; Obrador, Gregorio T.; Waikar, Sushrut S.; Wanner, Christoph; Wheeler, David C.; Więcek, Andrzej; Blackorby, Allison; Cizman, Borut (16 December 2021). "Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis". New England Journal of Medicine. 385 (25): 2313–2324. doi:10.1056/NEJMoa2113380. ISSN 0028-4793. PMID 34739196. S2CID 243761990.
External links
- Clinical trial number NCT02879305 for "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)" at ClinicalTrials.gov